Boehringer races to catch up in NASH through Yuhan deal

Boehringer races to catch up in NASH through Yuhan deal

Source: 
BioCentury
snippet: 

Boehringer is playing catch up in NASH through a preclinical deal with Yuhan that doubles its programs in the indication from one to two and marks its entry into combining therapeutic MOAs -- a strategy the field has pegged as the best bet for attacking the disease.